BofA analyst Tazeen Ahmad raised the firm’s price target on Amicus to $17 from $16 and keeps a Buy rating on the shares. The firm is confident in AT-GAA’s approvability based on its differentiated profile and totality of data and is encouraged to see progress on the WuXi facility inspection. BofA added that progress on EU approval "generally bodes well" for the U.S. approval.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on FOLD:
- Amicus announces European Commission approval for Pombiliti
- Amicus Therapeutics Announces European Commission Approval for Pombiliti™ in Patients with Late-Onset Pompe Disease
- Stifel says SVB fallout ‘appears limited’ across firm’s biotech coverage
- Amicus sees FY23 Galafold revenue growth between 12%-17% at CER
- Amicus Therapeutics Announces Full-Year 2022 Financial Results and Corporate Updates